Piramal Pharma shares up nearly 3% after U.S. launch of Chlorpromazine Hydrochloride Injection

Shares of Piramal Pharma Limited gained nearly 3% following the announcement that its division, Piramal Critical Care (PCC), has launched Chlorpromazine Hydrochloride for Injection, USP, in the U.S. market. This new offering comes in 25mg/1mL and 50mg/2mL vials and marks another milestone in PCC’s growing portfolio of generic injectables.

Key Highlights:

Advertisement

  • Product Launch: Chlorpromazine Hydrochloride is primarily used to manage severe nausea, vomiting, and psychotic disorders.
  • Portfolio Expansion: PCC has been consistently strengthening its presence in the generic injectables space. In 2024, the company introduced Edaravone IV Infusion as a first-to-market generic. Other notable additions include Pantoprazole Sodium for Injection, USP, and Doxycycline for Injection, USP, in 2023.
  • Commitment to Innovation: PCC’s continued expansion highlights its focus on providing high-quality, affordable solutions for critical care needs.

The latest launch underscores PCC’s dedication to innovation and accessibility in healthcare, further solidifying its position as a leader in the generic injectables sector.